Ketoprofen and Hepatocellular damage aggravated - a phase IV clinical study of FDA data

Summary:

Hepatocellular damage aggravated is reported as a side effect among people who take Ketoprofen (ketoprofen), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Omeprazole, and have High blood cholesterol.

The phase IV clinical study analyzes which people have Hepatocellular damage aggravated when taking Ketoprofen. It is created by eHealthMe based on reports of 14,955 people who have side effects when taking Ketoprofen from the FDA, and is updated regularly.

What is Ketoprofen?

Ketoprofen has active ingredients of ketoprofen. It is often used in pain. eHealthMe is studying from 15,048 Ketoprofen users. Check the latest studies of Ketoprofen.

What is Hepatocellular damage aggravated?

Hepatocellular damage aggravated (serious liver damage) is found to be associated with 501 drugs and 192 conditions by eHealthMe. Check the latest studies of Hepatocellular damage aggravated.

On Jul, 11, 2026

14,955 people reported to have side effects when taking Ketoprofen.
Among them, 24 people (0.16%) have Hepatocellular damage aggravated.

Could Ketoprofen cause Hepatocellular damage aggravated?

Among these 24 people:

How long have people been on Ketoprofen when they have Hepatocellular damage aggravated? *

What is the gender of people who have Hepatocellular damage aggravated when taking Ketoprofen? *

female: 66.67 %
male: 33.33 %

What is the age of people who have Hepatocellular damage aggravated when taking Ketoprofen? *

What are other drugs people take besides Ketoprofen? *

What are other side effects people have besides Hepatocellular damage aggravated? *

Rhabdomyolysis (a condition in which damaged skeletal muscle tissue breaks down): 8 people, 33.33%
Hepatic Steatosis (fatty liver disease): 6 people, 25.00%
Chest Pain: 6 people, 25.00%
Depression: 5 people, 20.83%
Night Sweats (sweating in night): 5 people, 20.83%
Haemoglobin Decreased: 5 people, 20.83%
Myocardial Ischaemia (the blood flow through one or more of the blood vessels that lead to heart (coronary arteries) is decreased): 5 people, 20.83%
Indigestion: 5 people, 20.83%
Infectious Mononucleosis (infection usually caused by the epstein-barr virus): 5 people, 20.83%
Platelet Count Increased: 4 people, 16.67%

What are the existing conditions these people have? *

High Blood Cholesterol: 5 people, 20.83%
Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 4 people, 16.67%
Back Pain: 3 people, 12.50%
Sedation: 2 people, 8.33%
Oesophagitis (inflammation of oesophagus): 1 person, 4.17%

* Approximation only. Some reports may have incomplete information.

Do you take Ketoprofen and have Hepatocellular damage aggravated?

- Check whether Hepatocellular damage aggravated is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Ketoprofen:

Ketoprofen (15,048 reports)

Browse all side effects of Ketoprofen:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hepatocellular damage aggravated:

Hepatocellular damage aggravated (501 drugs)

Browse all the conditions that are associated with Hepatocellular damage aggravated:

Hepatocellular damage aggravated (192 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on ketoprofen (the active ingredients of Ketoprofen) and Ketoprofen (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.